DNTH · Dianthus Therapeutics, Inc. /DE/
$115.96
+6.36 (+5.80%)
At close · Aug 14
Market Cap
$6.49B
Shares
55.93M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.04M
-67.3%
FY2025
Net Income
-$162.34M
-91.1%
FY2025
Operating Margin
-8739.34%
-7105.6pp
FY2025
Diluted EPS
-$4.20
-64.7%
FY2025
Operating Cash Flow
-$129.06M
-65.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $2.04M | $6.24M | $2.83M | $6.42M | $1.48M | — | $0 | $0 | $0 | $0 | |
| $175.6M | $145.64M | $83.11M | $32.84M | $29.38M | $46.77M | $50.62M | $59.21M | $41.34M | $27.9M | $5.78M | |
| $44.15M | $34.33M | $24.99M | $18.16M | $6.74M | $27.93M | $28.09M | $23.76M | $18.62M | $7.83M | $3.49M | |
| — | — | — | — | $1.93M | $2.02M | $1.98M | $1.84M | $875K | $376K | $6000 | |
| $219.75M | $179.97M | $108.1M | $51M | $36.12M | $74.69M | $78.7M | $82.97M | $59.96M | $35.73M | $9.27M | |
| -$217.84M | -$177.93M | -$101.86M | -$48.17M | -$29.71M | -$74.69M | -$78.7M | -$82.97M | -$59.96M | -$35.73M | -$9.27M | |
| — | -8739.34% | -1633.74% | -1704.67% | -462.91% | -5060.43% | — | — | — | — | — | |
| — | — | — | — | -$27.78M | -$72.67M | -$76.72M | -$81.13M | -$59.09M | -$35.35M | -$9.26M | |
| — | — | — | — | — | — | — | — | — | — | $163K | |
| $16.69M | $9.96M | $11.35M | $3.34M | — | — | — | — | — | — | — | |
| $25.6M | $15.6M | $16.9M | $4.62M | $1.23M | -$23K | — | — | $2.45M | $236K | -$163K | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$192.25M | -$162.34M | -$84.97M | -$43.56M | -$28.48M | -$71.14M | -$74.94M | -$76.77M | -$57.52M | -$35.49M | -$9.43M | |
| — | -7973.33% | -1362.77% | -1541.22% | -443.76% | -4819.51% | — | — | — | — | — | |
| — | — | — | — | — | — | — | -$76.77M | -$57.6M | -$35.51M | -$9.74M | |
| -$194.47M | -$161.95M | -$84.91M | -$43.35M | -$28.64M | -$71.14M | -$74.97M | -$76.75M | -$57.52M | -$35.49M | -$9.43M | |
| USD/shares | — | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 | -$1.71 | — | — | — | — |
| USD/shares | — | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 | -$1.71 | — | — | — | — |
| shares | — | 38.62M | 33.31M | 5.15M | 874.23K | 54.95M | 43.92M | 37.01M | 18.39M | 1.86M | 149.41K |
| shares | — | 38.62M | 33.31M | 5.15M | 874.23K | 54.95M | 43.92M | 37.01M | 18.39M | 1.86M | 149.41K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.92×
EV/EBIT
—
Peer median 24.88×
P/E (TTM)
—
Peer median 17.38×
Peer medians compare against the 180 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| License | $2,036,000 | $326,000 | $0 |
Key facts
CIK
1690585
CUSIP
252828108
13F (30d)
260 filings
256 filers
Visit website
Investor relations